Boston Scientific (BSX)

Overall impact
C (57)

Commentary

Boston Scientific is an average overall performer. With a 'C' rating of 57.0 for overall impact (56th percentile compared to all companies), Boston Scientific ranks 8th out of 13 industry peers, behind Abbott, Smith & Nephew, Getinge and 4 others, and ahead of Baxter, Fresenius, Becton Dickinson and 2 others. On top material causes for Boston Scientific's industry (Healthcare Equipment), Boston Scientific performs well in Sustainable Use of Natural Resources (95.1 score), Equal Pay and Opportunity (95.6), Reduced Green House Gas Emissions (87.5) and 1 other cause where it received an 'A' score and performs poorly in Accountable Institutions (12.7 score), Improved Mental Health (32.8), Child and Maternal Health (37.2) and 4 other causes where it received a 'D' or 'F' score.
Impact
Cause BSX
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Founded
1979
Employees
53,000
Sector
Health Care
Industry
Health Care Equipment & Supplies
Sub-industry
Health Care Equipment
SASB industry
Medical Equipment & Supplies
Headquarters
Ma, United States
Share classes
BSX
Mission
Dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world.
Description
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios. It also provides devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems. Additionally, the company offers devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. Boston Scientific provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
Material causes
Ethos considers the following causes material for Boston Scientific, based on its industry sub-industry Health Care Equipment. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.